<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03724890</url>
  </required_header>
  <id_info>
    <org_study_id>MS201964_0001</org_study_id>
    <nct_id>NCT03724890</nct_id>
  </id_info>
  <brief_title>Study of Avelumab-M3814 Combinations</brief_title>
  <official_title>A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to evaluate a safe, tolerable recommended Phase II dose&#xD;
      (RP2D) and/or the maximum tolerated dose (MTD) of M3814 when given in combination with&#xD;
      avelumab with and without radiotherapy in participants with selected advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Anticipated">May 17, 2022</completion_date>
  <primary_completion_date type="Actual">June 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Occurrence of Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>From first study intervention to planned final assessment at 3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Occurrence of Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>From first study intervention to planned final assessment at 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part FE: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of M3814</measure>
    <time_frame>Pre-dose up to end of treatment at 268 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part FE: Maximum Observed Drug Concentration (Cmax) of M3814</measure>
    <time_frame>Pre-dose up to end of treatment at 268 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Occurrence of Treatment-emergent Adverse Events (TEAEs) and Treatment-related AEs According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) and Serious Adverse Events</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters, Vital Signs, Physical Examination, Electrocardiogram (ECG) Findings</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
    <description>Number of participants with clinically significant abnormalities will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Number of Participants With Status Assessed on Eastern Cooperative Oncology Group Performance Status (ECOG PS)</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Maximum Observed Drug Concentration (Cmax) of Avelumab</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 299 days; Part B: Pre-dose up to end of treatment at 451 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Minimum Observed Drug Concentration (Cmin) of Avelumab</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 299 days; Part B: Pre-dose up to end of treatment at 451 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Accumulation Ratio for Cmax [Racc(Cmax)] of Avelumab</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 299 days; Part B: Pre-dose up to end of treatment at 451 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Accumulation Ratio for AUC [Racc (AUC)] of Avelumab</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 299 days; Part B: Pre-dose up to end of treatment at 451 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Apparent Terminal Half-life (t1/2) of Avelumab</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 299 days; Part B: Pre-dose up to end of treatment at 451 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Maximum Observed Drug Concentration (Cmax) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Time to Reach the Maximum Plasma Concentration (tmax) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Minimum Observed Drug Concentration (Cmin) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Average Plasma Concentration of M3814 Observed Post-dose (Cavg)</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Fluctuation Index of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Accumulation ratio for Cmax [Racc(Cmax)] of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Accumulation ratio for AUC [Racc(Auc)] of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Apparent Terminal Half-life (t1/2) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Apparent Volume of Distribution During Terminal Phase (Vz/f) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Apparent Clearance (CL/f) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: Terminal Elimination Rate Constant (λz) of M3814</measure>
    <time_frame>Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Number of Participants With Positive Antidrug Antibody (ADA) Assay</measure>
    <time_frame>Part A and FE: From the first study intervention to planned final assessment at 299 days; Part B: From the first study intervention to planned final Part B assessment at 451 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Best Overall Response (BOR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1)</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Duration of Response (DOR) as Assessed by the Investigators According to RECIST v 1.1</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Progression-free Survival (PFS) Time According to RECIST v 1.1 Assessed by Investigator</measure>
    <time_frame>Part A and FE: From baseline to planned final assessment at 305 days; Part B: From baseline to planned final assessment at 473 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Tumor size Based on Investigator Assessment According to RECIST v 1.1</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A, B and FE: Overall Survival</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants with Radiotherapy (RT)-induced Toxicity According to NCI-CTCAE v 5.0</measure>
    <time_frame>From the first study intervention to planned final assessment at 508 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Oncology</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part A: M3814 + Avelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: M3814 + Avelumab + Radiotherapy (RT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part FE: M3814 + Avelumab (fasted/fed state)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M3814</intervention_name>
    <description>Participants will receive M3814 twice daily (BID) continuously starting from Day 1 until progressive disease (PD) or unacceptable toxicity.</description>
    <arm_group_label>Part A: M3814 + Avelumab</arm_group_label>
    <arm_group_label>Part FE: M3814 + Avelumab (fasted/fed state)</arm_group_label>
    <other_name>Peposertib</other_name>
    <other_name>MSC2490484A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M3814</intervention_name>
    <description>Participants will receive M3814 concomitantly with RT once (QD) daily starting Day 1 for 5 days per week for 2 weeks in total.</description>
    <arm_group_label>Part B: M3814 + Avelumab + Radiotherapy (RT)</arm_group_label>
    <other_name>Peposertib</other_name>
    <other_name>MSC2490484A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Participants will receive avelumab once every 2 weeks (Q2W) starting from Day 1 until PD or unacceptable toxicity.</description>
    <arm_group_label>Part A: M3814 + Avelumab</arm_group_label>
    <arm_group_label>Part B: M3814 + Avelumab + Radiotherapy (RT)</arm_group_label>
    <arm_group_label>Part FE: M3814 + Avelumab (fasted/fed state)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Participants will receive radiotherapy at the dose of 3 grays (Gy) per day starting Day 1 for 5 days per week for 2 weeks.</description>
    <arm_group_label>Part B: M3814 + Avelumab + Radiotherapy (RT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part A and Part FE (M3814 + avelumab): Participants must have histologically or&#xD;
             cytologically proven advanced or metastatic solid tumors for which no standard therapy&#xD;
             exists, standard therapy has failed, or participants are intolerant to or have&#xD;
             rejected established therapy known to provide clinical benefit for their condition&#xD;
&#xD;
          -  Part B (M3814 + Radiotherapy [RT] + avelumab): histologically or cytologically proven&#xD;
             advanced or metastatic solid tumors for which no standard therapy exists, standard&#xD;
             therapy has failed, or participants are intolerant to or have rejected established&#xD;
             therapy known to provide benefit for their condition and are amenable to receive RT&#xD;
&#xD;
          -  Part A, B and FE: Measurable or evaluable disease according to Response Evaluation&#xD;
             Criteria in Solid Tumors Version 1.1 (RECIST v 1.1)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 at study&#xD;
             entry&#xD;
&#xD;
          -  Part A, B and FE: Female participants of childbearing potential should be willing to&#xD;
             use a highly effective contraceptive method&#xD;
&#xD;
          -  Part A, B and FE: Male participants should agree to refrain from donating sperm plus,&#xD;
             either: abstain from any activity that allows for exposure to ejaculate&#xD;
&#xD;
          -  Use an adequate method of contraception starting with the first dose of study therapy&#xD;
             through 90 days after the last dose of study therapy&#xD;
&#xD;
          -  Part A, B and FE: Be willing to provide informed consent for the trial&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who have received prior chemotherapy, hormonal anticancer therapy with&#xD;
             the exception of luteinizing hormone-releasing hormone analogs, biologic therapy, or&#xD;
             any other anticancer therapy within 28 days of the first dose of study treatments (6&#xD;
             weeks for nitrosoureas or mitomycin C)&#xD;
&#xD;
          -  Participants who have undergone major surgery for any reason, except diagnostic&#xD;
             biopsy, within 4 weeks of the study intervention and/or has not fully recovered from&#xD;
             the surgery within 4 weeks of the study intervention&#xD;
&#xD;
          -  Participants with evidence of active or history of autoimmune disease that might&#xD;
             deteriorate when receiving an immune-stimulatory agent&#xD;
&#xD;
          -  Participants with brain metastases, except those meeting the following criteria: a)&#xD;
             brain metastases that have been treated locally and are clinically stable for greater&#xD;
             than or equal to (&gt;=) 4 weeks prior to randomization b) no ongoing neurological&#xD;
             symptoms that are related to the brain localization of the disease (sequelae that are&#xD;
             a consequence of the treatment of the brain metastases are acceptable) c) participants&#xD;
             must be either off steroids or on a stable or decreasing dose of less than (&lt;) 10&#xD;
             milligrams (mg) daily prednisone (or equivalent)&#xD;
&#xD;
          -  Participants with severe acute or chronic medical conditions including immune colitis,&#xD;
             inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric&#xD;
             conditions including recent (within the past year), psychiatric or substance abuse&#xD;
             disorders; or active suicidal ideation or behavior; or laboratory abnormalities that&#xD;
             may increase the risk associated with study participation or study intervention&#xD;
             administration or may interfere with the interpretation of study results&#xD;
&#xD;
          -  Participants requiring systemic immunosuppressive agents (such as steroids) for any&#xD;
             reason who cannot be tapered off these drugs before start of study intervention, with&#xD;
             the following exceptions: a) participants with adrenal insufficiency, may continue&#xD;
             corticosteroids at physiologic replacement dose, equivalent to less than or equal to&#xD;
             (&lt;=) 10 mg prednisone daily b) participants requiring steroids through a route known&#xD;
             to result in a minimal systemic exposure (topical, intranasal, intra-ocular, or&#xD;
             inhalation) is permitted c) participants with previous or ongoing administration of&#xD;
             systemic steroids for the management of an acute allergic phenomenon planned to be&#xD;
             completed in 14 days, or that the dose after 14 days will be equivalent to &lt;= 10 mg&#xD;
             prednisone daily&#xD;
&#xD;
          -  Participants with a history of human immunodeficiency virus (HIV) or known acquired&#xD;
             immunodeficiency syndrome, Hepatitis B virus or Hepatitis C and with history of&#xD;
             infection must have a polymerase chain reaction (PCR) documentation that infection is&#xD;
             cleared&#xD;
&#xD;
          -  Participants who have received a live vaccine within 30 days prior to the first dose&#xD;
             of trial treatment&#xD;
&#xD;
          -  Participants with known prior severe hypersensitivity to any of the investigational&#xD;
             products or any component in its formulations&#xD;
&#xD;
          -  Participants with evidence of additional malignancy within the last 5 years unless a&#xD;
             complete remission without further recurrence was achieved at least 2 years prior to&#xD;
             study entry and participants were deemed to have been cured with no additional therapy&#xD;
             required or anticipated to be required. Participants with treated nonmelanoma skin&#xD;
             cancers, carcinoma in situ of skin, bladder, cervix, colon/rectum, breast, or prostate&#xD;
             may participate&#xD;
&#xD;
          -  Participants pretreated with immunotherapy who have, any history of dose limiting&#xD;
             toxicities (DLTs) with prior immunotherapy agents, including Grade 3/4 immune-related&#xD;
             adverse events (irAEs); irreversible irAEs; Grade greater than or equals to (&gt;=) 3&#xD;
             irAEs that did not respond to steroid rescue; or neurologic irAE with significant&#xD;
             clinical sequelae&#xD;
&#xD;
          -  Participants with irAE requiring hormone replacement therapy (e.g., thyroxine,&#xD;
             insulin, or physiologic dose of corticosteroid replacement therapy for adrenal or&#xD;
             pituitary insufficiency) may participate as long as the endocrinopathy is well&#xD;
             controlled and the participant is not otherwise symptomatic from hormone insufficiency&#xD;
&#xD;
          -  Physiologic corticosteroid dose is defined as &lt;= 10 mg daily of prednisone or&#xD;
             equivalent&#xD;
&#xD;
          -  for Part B only:&#xD;
&#xD;
          -  Participants who have confirmed esophagitis and in whom radiation planning target&#xD;
             volume will include any portion of the esophagus, the participant is not eligible&#xD;
             unless an esophageal endoscopy rules out the presence of esophagitis&#xD;
&#xD;
          -  Participants in whom more than 10 percent (%) of the total esophagus volume might&#xD;
             receive more than 15 gray (Gy) (50% of the prescribed radiotherapy [RT] dose)&#xD;
&#xD;
          -  Participants who have had previous radiotherapy to the same region as intended to be&#xD;
             irradiated in this study within the past 12 months&#xD;
&#xD;
          -  Participants who have had extensive previous radiotherapy on &gt;= 30% of bone marrow&#xD;
             reserve or prior bone marrow/stem cell transplantation within 5 years before study&#xD;
             start&#xD;
&#xD;
          -  If participant hepatic metastatic lesion is selected to be irradiated: - the non-tumor&#xD;
             liver volume &lt; 700 milli liters (mL); - Child-Pugh score &gt;= 8&#xD;
&#xD;
          -  Other protocol defined exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>eMediUSA@emdserono.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72</phone>
    <phone_ext>5200</phone_ext>
    <email>service@emdgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Marin Cancer Care, Inc. - Pharmatech Oncology, Inc.</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>peisenberg@marincancercare.com</email>
    </contact>
    <investigator>
      <last_name>Peter D Eisenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai - PRIME (10707)</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Health Clinical Trials Office (10702)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>morri2j7@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>John C Morris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center - Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Health System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jluke@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Jason J Luke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System University Medical Center (ITOR)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>william.edenfield@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>William J Edenfield</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center (8867)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>wade.iams@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Wade Iams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS201964_0001</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Palliative Radiotherapy</keyword>
  <keyword>Advanced solid tumors</keyword>
  <keyword>M3814</keyword>
  <keyword>Avelumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avelumab</mesh_term>
    <mesh_term>Peposertib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

